مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

197
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

110
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series (BRIEF REPORT)

Pages

  0-0

Abstract

 Introduction: Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist that can block ADPinduced platelet aggregation. This study aimed to describe one-month follow-up findings of cases undergoing Ticagrelor therapy after percutaneous coronary intervention (PCI). Methods: This case series was performed on acute coronary syndrome (ACS) patients who were candidates for PCI and received aspirin plus Ticagrelor after PCI. Patients were followed for one month and their outcomes were described. Results: 156 cases with the mean age of 59. 74 § 9. 24 years were studied (63% male). 45 (28. 8%) cases complained of dyspnea (39 cases with mild and 6 cases with severe dyspnea). Bleeding occurred in 4 (2. 5%) cases (intra-cranial hemorrhage (ICH) in one, hematuria in two, and skin hemorrhage in one case). There were no cases with bradycardia or thrombosis. One (0. 6%) patient developed drug hypersensitivity reaction, which manifested as skin rash. The use of drug was stopped in 10 (6. 4%) cases due to severe dyspnea (n= 6), ICH (n=1), skin rash (n=1), and concomitant left ventricular (LV) clot (n=2). Conclusion: The most important finding of one-month Ticagrelor consumption were dyspnea, bleeding, and hypersensitivity reaction. No case of bradycardia and stent thrombosis was detected. In our study, iranian population has more susceptibility to dyspnea than PLATO result. The rate of drug discontinuation in this series of cases was 6. 4%.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    NAMAZI, MOHAMMAD HASAN, Saemifard, Farzam, & PISHGAHI, MEHDI. (2020). One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series (BRIEF REPORT). ARCHIVES OF ACADEMIC EMERGENCY MEDICINE (EMERGENCY), 8(1), 0-0. SID. https://sid.ir/paper/339882/en

    Vancouver: Copy

    NAMAZI MOHAMMAD HASAN, Saemifard Farzam, PISHGAHI MEHDI. One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series (BRIEF REPORT). ARCHIVES OF ACADEMIC EMERGENCY MEDICINE (EMERGENCY)[Internet]. 2020;8(1):0-0. Available from: https://sid.ir/paper/339882/en

    IEEE: Copy

    MOHAMMAD HASAN NAMAZI, Farzam Saemifard, and MEHDI PISHGAHI, “One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series (BRIEF REPORT),” ARCHIVES OF ACADEMIC EMERGENCY MEDICINE (EMERGENCY), vol. 8, no. 1, pp. 0–0, 2020, [Online]. Available: https://sid.ir/paper/339882/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button